| CPC A61B 17/3403 (2013.01) [A61B 17/3478 (2013.01); A61B 18/00 (2013.01); A61B 18/04 (2013.01); A61B 18/06 (2013.01); A61B 18/1492 (2013.01); A61M 25/0084 (2013.01); A61B 2018/00214 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00279 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00517 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/046 (2013.01); A61B 2018/143 (2013.01); A61B 2018/1432 (2013.01); A61B 2018/1475 (2013.01); A61B 2090/3966 (2016.02); A61B 2218/002 (2013.01); A61M 2025/0087 (2013.01); A61M 25/10 (2013.01)] | 20 Claims |

|
1. A transvascular method of minimizing pain during the treatment of extravascular tissue, comprising:
providing a catheter having an elongate flexible body, a proximal end, a distal end, and a needle disposed within a lumen of a guide tube;
transvascularly positioning the distal end of the catheter at a treatment site;
deploying the needle into a vessel wall at a depth of more than 0.5 mm from an inside surface of the vessel wall while maintaining the guide tube against the vessel wall, without the guide tube puncturing the vessel wall;
a single injection of an ablative agent with a first flow rate for desensitizing pain nerves by injecting the ablative agent through the needle wherein the ablative fluid spreads out both radially and circumferentially and a second flow rate for ablating sympathetic nerves by injecting the ablative agent through the needle.
|